Uncategorized
VIDEO: Santen initiates phase three studies of omidenepag for glaucoma
CHICAGO — At the American Academy of Ophthalmology meeting here, Ellie Chabi, MD, the therapeutic area head for glaucoma and neuroprotection and the lead for artificial intelligence programs within global biomedical science at Santen, discusses the initiation of two phase 3 clinical trials of omidenepag isopropyl for the treatment of glaucoma and ocular hypertension.